Ovarian neoplasm: genes and variants
Explore variant evidence for Ovarian neoplasm across 11 analyzed proteins (PIK3CA, TP53, BRCA1, BRCA2, PARP2 and 6 more). Linked ClinVar records include 10 pathogenic or likely pathogenic variants, 7 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Ovarian neoplasm
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
5 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PIK3CA have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TP53 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
BRCA1: Breast cancer type 1 susceptibility protein
It coordinates DNA-damage signaling and homologous-recombination repair while helping protect stalled replication forks and chromosome integrity. Germline loss-of-function variants strongly predispose to breast and ovarian cancer and increase risk for several other malignancies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRCA1 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
BRCA2: Breast cancer type 2 susceptibility protein
It loads RAD51 onto damaged DNA to enable homologous recombination and also protects stressed replication forks from degradation. Germline loss-of-function variants strongly predispose to breast, ovarian, prostate, pancreatic, and other cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRCA2 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
PARP2: Poly [ADP-ribose] polymerase 2
It cooperates with PARP1 in sensing DNA damage and promoting poly(ADP-ribose)-dependent repair, particularly at single-strand breaks. Its activity contributes to the response to PARP inhibitors and to DNA-repair redundancy in cancer cells.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PARP2 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
TOP1: DNA topoisomerase 1
It relieves torsional strain in DNA by creating and resealing transient single-strand breaks during replication and transcription. Trapping of the cleavage intermediate is the mechanism exploited by topoisomerase I inhibitors such as irinotecan and topotecan in cancer therapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TOP1 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
TOP2A: DNA topoisomerase 2-alpha
It resolves DNA tangles and supercoils by passing one double helix through a transient double-strand break in another, a process essential during replication and chromosome segregation. It is the target of widely used anticancer drugs including anthracyclines and etoposide.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TOP2A have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
ERBB2: Receptor tyrosine-protein kinase erbB-2
ERBB2, also called HER2, is a cell-surface receptor tyrosine kinase that works with other ERBB receptors to transmit growth signals. It helps organize signaling and cytoskeletal responses, and abnormal ERBB2 activity is a major feature of several cancers.
2 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ERBB2 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
CTNNB1: Catenin beta-1
It links cadherins to the cytoskeleton at adherens junctions and, when stabilized by Wnt signaling, enters the nucleus to regulate transcription. Activating somatic variants drive many cancers, while germline loss-of-function variants cause CTNNB1 neurodevelopmental disorder.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in CTNNB1 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
BRIP1: Fanconi anemia group J protein
It unwinds DNA structures and works with BRCA1 and the Fanconi-anemia pathway to repair damaged replication intermediates and interstrand crosslinks. Biallelic loss causes Fanconi anemia group J, while heterozygous loss-of-function variants increase ovarian-cancer risk.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRIP1 have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
PRKN: E3 ubiquitin-protein ligase parkin
Its parkin ubiquitin-ligase activity marks damaged mitochondrial proteins after PINK1 activation and helps eliminate dysfunctional mitochondria through mitophagy. Biallelic loss-of-function variants are a major cause of autosomal recessive juvenile or early-onset Parkinson disease.
0 ClinVar pathogenic / likely pathogenic and 5 uncertain variants in PRKN have source records linked to Ovarian neoplasm. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): FGFR3, MSH2, PTEN and RB1.
ClinVar pathogenic and likely pathogenic variants linked to Ovarian neoplasm
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PIK3CA E545A | 545 | PIK helical | Pathogenic / likely pathogenic (★★) |
| PIK3CA N345K | 345 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PIK3CA Q546R | 546 | PIK helical | Pathogenic / likely pathogenic (★★) |
| TP53 C176R | 176 | DNA binding | Pathogenic / likely pathogenic |
| BRIP1 Q793H | 793 | Pathogenic / likely pathogenic | |
| CTNNB1 S37C | 37 | Pathogenic / likely pathogenic | |
| ERBB2 N824S | 824 | Protein kinase | Pathogenic / likely pathogenic |
| PIK3CA V344G | 344 | C2 PI3K-type | Pathogenic / likely pathogenic |
| PIK3CA E542Q | 542 | PIK helical | Pathogenic / likely pathogenic |
| ERBB2 N857S | 857 | Protein kinase | Pathogenic / likely pathogenic |
Which prediction tools work for Ovarian neoplasm
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- PolyPhen-2: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 85 out of 100
- SIFT: 74 out of 100
- CATVariant: 73 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 68 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 67 out of 100
- MetaSVM: 44 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 39 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- PIK3CA related overgrowth syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Ovarian neoplasm variants (30 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Ovarian neoplasm variants (23 pathogenic / likely pathogenic).
- Megalencephaly-capillary malformation-polymicrogyria syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Ovarian neoplasm variants (22 pathogenic / likely pathogenic).
- PIK3CA constitutional syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Ovarian neoplasm variants (4 pathogenic / likely pathogenic).
- Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Ovarian neoplasm variants (4 pathogenic / likely pathogenic).
- Urinary bladder cancer also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Ovarian neoplasm variants (6 pathogenic / likely pathogenic).
- Lung adenocarcinoma also has ClinVar records linked to ERBB2 variants; they fall mostly in different places as the Ovarian neoplasm variants (3 pathogenic / likely pathogenic).
- Pilomatrixoma also has ClinVar records linked to CTNNB1 variants; they fall partly in the same places as the Ovarian neoplasm variants (8 pathogenic / likely pathogenic).
- Severe intellectual disability-progressive spastic diplegia syndrome also has ClinVar records linked to CTNNB1 variants; they fall mostly in different places as the Ovarian neoplasm variants (5 pathogenic / likely pathogenic).
- Medulloblastoma also has ClinVar records linked to CTNNB1 variants; they fall mostly in different places as the Ovarian neoplasm variants (4 pathogenic / likely pathogenic).
- Li-Fraumeni syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Ovarian neoplasm variants (188 pathogenic / likely pathogenic).
- Adrenocortical carcinoma, hereditary also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Ovarian neoplasm variants (23 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Ovarian neoplasm variants (6 pathogenic / likely pathogenic).
- Hereditary breast ovarian cancer syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Ovarian neoplasm variants (6 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Ovarian neoplasm variants (5 pathogenic / likely pathogenic).
Diseases related to Ovarian neoplasm
- Ovarian cancer, also linked to BRCA1, BRCA2, BRIP1, CTNNB1 and 6 more
- Hereditary breast cancer, also linked to BRCA1, BRCA2, BRIP1, PIK3CA and 1 more
- Colorectal cancer, also linked to CTNNB1, ERBB2, PIK3CA, TOP1 and 1 more
- Hereditary breast ovarian cancer syndrome, also linked to BRCA1, BRCA2, BRIP1 and TP53
- Gastric cancer, also linked to BRIP1, ERBB2, PIK3CA and TP53
- Urinary bladder cancer, also linked to CTNNB1, ERBB2, PIK3CA and TP53
- Fanconi anemia complementation, also linked to BRCA1, BRCA2 and BRIP1
- Non-small cell lung carcinoma, also linked to ERBB2, PIK3CA and TOP1
- Glioma susceptibility, also linked to BRCA2, ERBB2 and TP53
- Lung cancer, also linked to ERBB2, PIK3CA and PRKN
- Hepatocellular carcinoma, also linked to CTNNB1, PIK3CA and TP53
- Prostate cancer, also linked to BRCA2, PARP2 and TOP2A
Frequently asked questions
Which genes have records linked to Ovarian neoplasm?
This view contains 11 analyzed proteins: PIK3CA, TP53, BRCA1, BRCA2, PARP2 and 6 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 10 pathogenic or likely pathogenic variants, 7 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 25 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center